The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SBP-101, a polyamine metabolic inhibitor, administered in combination with gemcitabine and nab-paclitaxel, shows signals of efficacy as first-line treatment for subjects with metastatic pancreatic ductal adenocarcinoma.
 
Nimit Singhal
No Relationships to Disclose
 
Darren Sigal
Stock and Other Ownership Interests - Bristol-Myers Squibb; Celularity; DrugCendR; Halozyme; Johnson & Johnson; Karyopharm Therapeutics; Mirati Therapeutics; Molecular Stethoscope; Novartis
Consulting or Advisory Role - Halozyme
Speakers' Bureau - Bayer; Celgene
Research Funding - Abivax; ARIAD/Incyte; halozyme; OBI Pharma; Sun Biopharma
Patents, Royalties, Other Intellectual Property - Patent on "a method for treating neuroendocrine tumors" using TRK inhibitors.
 
Niall C. Tebbutt
Honoraria - Bristol-Myers Squibb; Pierre Fabre; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Pierre Fabre; Roche
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bayer
 
Aram F Hezel
No Relationships to Disclose
 
Adnan Nagrial
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Roche
Research Funding - Akeso Biopharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst)
 
Sumit Lumba
No Relationships to Disclose
 
Thomas J. George
Consulting or Advisory Role - Tempus
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Seagen (Inst); Tesaro (Inst)
 
Sheri Lynn Smith
Employment - Courante Oncology
Leadership - Courante Oncology
Stock and Other Ownership Interests - Courante Oncology
Consulting or Advisory Role - Asymmetric Therapeutics; Inceptua; Pillar Biosciences; Tanner Pharma
 
Suzanne Gagnon
Employment - Panbela Therapeutics
Leadership - Panbela Therapeutics
Stock and Other Ownership Interests - Panbela Therapeutics
Consulting or Advisory Role - Provepharm
Research Funding - Panbela Therapeutics
Patents, Royalties, Other Intellectual Property - Panbela Therapeutics
Travel, Accommodations, Expenses - Panbela Therapeutics
 
Michael Walker
Employment - Panbela Therapeutics
Stock and Other Ownership Interests - Panbela Therapeutics
Consulting or Advisory Role - Panbela Therapeutics
Research Funding - Panbela Therapeutics
Patents, Royalties, Other Intellectual Property - Method of Dosing SBP-101
Travel, Accommodations, Expenses - Panbela Therapeutics
 
Michael T. Cullen
Employment - Panbela Therapeutics
Stock and Other Ownership Interests - Panbela Therapeutics
Consulting or Advisory Role - Panbela Therapeutics
Research Funding - Panbela Therapeutics
Patents, Royalties, Other Intellectual Property - Panbela Therapeutics
Travel, Accommodations, Expenses - Panbela Therapeutics